12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cypress Pharmaceutical, Pernix Therapeutics deal

Pernix completed its acquisition of generics company Cypress and its Hawthorn Pharmaceuticals Inc. branded pharmaceutical subsidiary for $102 million comprising $52 million...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >